Development of next-generation allosteric compounds for the GLP-1R based on human receptor variants to treat type 2 diabetes – alloGLP1R
The glucagon-like-peptide-1 receptor (GLP-1R), a class B G protein-coupled receptor (GPCR), is a well-validated target for the treatment of type 2 diabetes mellitus (T2DM) with several peptide agonists on the market. These drugs improve glycemic control and reduce body weight but suffer also from side effects such as nausea and vomiting and require parenteral administration reducing patient adherence of this in life-long therapy. Small molecules that act as GLP-1R allosteric modulators emerged recently as a promising alternative. We propose here to identify functionally relevant allosteric binding sites at the GLP-1R based on natural GLP-1R variants, to identify binders at this site by virtual screening and to characterize their functional properties.
Project coordination
Ralf JOCKERS (Institut Cochin)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
Partner
Imperial College London / Section of Endocrinology and Investigative Medicine
INSERM Institut Cochin
LIT Laboratoire d'Innovation Thérapeutique (UMR 7200)
Help of the ANR 515,679 euros
Beginning and duration of the scientific project:
September 2021
- 48 Months